{"classes":[{"categories":[{"measurements":[{"comment":"Due to insufficient number of participants the median of duration of MRD negativity could not be accurately obtained.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Due to insufficient number of participants the median of duration of MRD negativity could not be accurately obtained.","groupId":"OG001","spread":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"Duration of MRD negativity (10\\^-5) was defined as the time from the first MRD negative status (10\\^-5) to the earliest date of the MRD positive status (10\\^-5), confirmed PD per IMWG or death.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received modakafusp alfa 120 mg, infusion, IV, Q4W, for each 28-day treatment cycle until disease progression or treatment discontinuation.","id":"OG000","title":"Part 3 (Dose Extension): Modakafusp Alfa 120 mg"},{"description":"Participants received modakafusp alfa 240 mg, infusion, IV, Q4W, for each 28-day treatment cycle until disease progression or treatment discontinuation.","id":"OG001","title":"Part 3 (Dose Extension): Modakafusp Alfa 240 mg"}],"paramType":"MEDIAN","populationDescription":"The ITT Analysis Set included all randomized participants regardless of whether they received study drug or adhered to the assigned dose. Overall number of participants analyzed is the number of participants from ITT analysis set who achieved CR.","reportingStatus":"POSTED","timeFrame":"Up to 20.5 months in Part 3","title":"Part 3: Duration of MRD Negativity Status at a Sensitivity of 10^-5 in Participants Achieving CR","type":"SECONDARY","unitOfMeasure":"months"}